Condition: COVID-19 · Sponsor: Kirby Institute
It is important people receiving immunosuppressive therapy are provided with the best protection against COVID-19 because they are at greater risk of severe illness should they become infected. As severe immunosuppression can reduce the efficacy of COVID-19 vaccination, doctors agree that COVID-19 boosters is are important to maximise the vaccine response in these people. However, we don't currently know the best time to give booster vaccines to people about to start immunosuppressive therapy. This research aims to address this knowledge gap by examining whether the greatest protection is provided by giving the COVID-19 booster just before the immunosuppressive therapy starts or by waiting and giving the booster 6 months after treatment start. At the 6-month timepoint, in many cases the more intensive immunosuppression is often weaning and the immune system is starting to rebuild.
This description comes directly from the study's public registry record.
Dianne L Carey, PhD · +61 2 9385 0908 · dcarey@kirby.unsw.edu.au
Always discuss trial participation with your own doctor first.
| Blacktown Hospital | Blacktown, New South Wales, Australia | Recruiting |
| Royal Prince Alfred Hospital | Camperdown, New South Wales, Australia | Recruiting |
| Concord General Repatriation Hospital | Concord, New South Wales, Australia | Recruiting |
| St Vincent's Hospital, Sydney | Darlinghurst, New South Wales, Australia | Recruiting |
| Westmead Hospital | Westmead, New South Wales, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05415267